Generic DLA = death



















There was once in time when DLA kicked our ass and we were just lucky enough to be there when Pf stumbled and screwed up their OAB franchise, don't get too cocky and forget where you came from or lest history repeat itself!
 






This isn't even about APUS screwing up. It's simple math. A generic priced DLA wil always always be the first choice for patients. It ain't oxy. This is a market driven almost solely by cost. We cannot compete financially. Myrbetriq will be 2nd line at best. Vesicare will have disappeared w/in 3 months of a generic hitting the market. Anyone who argues otherwise has no business sense.